These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10898188)

  • 1. Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease.
    Green DW; Roh H; Pippin J; Drebin JA
    J Am Coll Surg; 2000 Jul; 191(1):93-105. PubMed ID: 10898188
    [No Abstract]   [Full Text] [Related]  

  • 2. Antisense approaches for the treatment of cancer.
    Monia BP; Holmlund J; Dorr FA
    Cancer Invest; 2000; 18(7):635-50. PubMed ID: 11036471
    [No Abstract]   [Full Text] [Related]  

  • 3. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense approaches enter the clinic.
    Khuri FR; Kurie JM
    Clin Cancer Res; 2000 May; 6(5):1607-10. PubMed ID: 10815875
    [No Abstract]   [Full Text] [Related]  

  • 6. Crohn's trial shows the pros of antisense.
    Robertson D
    Nat Biotechnol; 1997 Mar; 15(3):209. PubMed ID: 9062911
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
    Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
    Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug treatment for Crohn's disease.
    Yacyshyn BR
    Lancet; 1998 Aug; 352(9129):743. PubMed ID: 9729027
    [No Abstract]   [Full Text] [Related]  

  • 9. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
    Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
    O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
    Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?
    Stewart A
    Mol Med Today; 1997 Aug; 3(8):324. PubMed ID: 9269683
    [No Abstract]   [Full Text] [Related]  

  • 12. Antisense oligonucleotides in lung cancer.
    Pujol JL; Jacot W
    Suppl Tumori; 2002; 1(4):S50-1. PubMed ID: 12415820
    [No Abstract]   [Full Text] [Related]  

  • 13. Tackling the real culprits in Crohn's disease.
    Bonn D
    Lancet; 1998 Jun; 351(9117):1710. PubMed ID: 9734899
    [No Abstract]   [Full Text] [Related]  

  • 14. Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications.
    Schumacher C; Cioffi CL; Sharif H; Haston W; Monia BP; Wennogle L
    Mol Pharmacol; 1998 Jan; 53(1):97-104. PubMed ID: 9443936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
    Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
    Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
    Roychowdhury D; Lahn M
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
    Geiger T; Müller M; Monia BP; Fabbro D
    Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase.
    Monia BP; Johnston JF; Geiger T; Muller M; Fabbro D
    Nat Med; 1996 Jun; 2(6):668-75. PubMed ID: 8640558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technology evaluation: LErafAON, NeoPharm.
    Moreira JN; Simões S
    Curr Opin Mol Ther; 2003 Oct; 5(5):547-52. PubMed ID: 14601525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease.
    Yacyshyn B; Bowen-Yacyshyn MB; Shanahan W
    Curr Opin Mol Ther; 1999 Jun; 1(3):332-5. PubMed ID: 11713798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.